Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding

Sexually Transmitted Diseases

Volumn 33, Issue 9, 2006, Pages 529-533

  Wald, Anna ^a,g   Selke, Stacy ^a   Warren, Terri ^b   Aoki, Fred Y ^c   Sacks, Stephen ^d   Diaz Mitoma, Francisco ^e   Corey, Lawrence ^a,f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Westover Heights Clinic   (United States)

^c Viridae Clinical Sciences Inc   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR; LIVER ENZYME; VALACICLOVIR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; APPENDIX PERFORATION; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; ELECTIVE SURGERY; ENZYME BLOOD LEVEL; FEMALE; GENITAL HERPES; HEART PALPITATION; HERPES SIMPLEX VIRUS 2; HIATUS HERNIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PERSONALITY DISORDER; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RISK FACTOR; THORAX PAIN; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS REACTIVATION; VIRUS SHEDDING;

2-AMINOPURINE; ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MALE; PATIENT COMPLIANCE; RECURRENCE; VALINE; VIRUS SHEDDING;

EID: 33748259433     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000204723.15765.91     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002;51:1-82.
2. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001;357:1513-1518.
3. Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995;333:770-775.
4. Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
5. Ashley RL, Militoni J, Lee F, et al. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26:662-667.
6. Jerome KR, Huang ML, Wald A, et al. Quantitative stability of DNA after extended storage of clinical specimens as determined by realtime PCR. J Clin Microbiol 2002; 40:2609-2611.
7. Loveless M, Harris W, Sacks S. Treatment of first episode genital herpes with famciclovir. Programs and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 1995.
8. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind randomized clinical trial. Sex Transm Dis 1997; 24:481-486.
9. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998; 178:603-610.
10. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190:1374-1381.
11. Conant MA, Schacker TW, Murphy RL, et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002; 13:12-21.
12. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Arch Intern Med 1997; 157:343-349.
13. Hodge RA, Cheng YC. The mode of action of penciclovir. Antiviral Chem Chemother 1993; 4:13-24.
14. Brigden D, Whitman P. The clinical pharmacology of acyclovir and its prodrug. Scand J Infect Dis Suppl 1985; 47:33.
15. Weinberg A, Bate B, Masters H, et al. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 1. Antimicrob Agents Chemother 1992; 36:2037-2038.
16. Elion G, Furman P, Fyfe J, et al. The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977; 74:5716-5720.
17. Thackray AM, Field HJ. Differential effects of famciclovir and valacyclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J Infect Dis 1996; 173:291-299.
18. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
19. Sacks SL, Griffiths PD, Corey L, et al. Introduction: is viral shedding a surrogate marker for transmission of genital herpes? Antiviral Res 2004; 63(suppl 1):S3-9.
20. Steinbrook R. Gag clauses in clinical-trial agreements. N Engl J Med 2005; 352:2160-2162.